Valuation: Acarix AB

Market Cap 30Cr 3.14Cr 2.73Cr 2.54Cr 2.33Cr 4.4Cr 299.52Cr 4.47Cr 12Cr 149.11Cr 12Cr 12Cr 500Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 30Cr 3.14Cr 2.73Cr 2.54Cr 2.33Cr 4.4Cr 299.52Cr 4.47Cr 12Cr 149.11Cr 12Cr 12Cr 500Cr EV / Sales 2026 *
15.7x
EV / Sales 2027 * 4.31x
Free-Float
83.24%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer - 01/02/2024
Chief Executive Officer 62 23/02/2018
Director TitleAgeSince
Director/Board Member 61 01/01/2020
Director/Board Member 52 14/05/2024
Director/Board Member - 14/05/2024
Change 5-day change 1-year change 3-year change Capi.($)
-1.89%-1.36%+16.24%-41.91% 1.57TCr
+4.47%+7.46%+1.25%+106.27% 177.35Cr
+1.21%+4.49%-27.15%-80.80% 114.36Cr
-1.73%+2.33%-38.79%+13.42% 98Cr
+1.29%+7.31%-46.81%-52.67% 65Cr
+0.93%+7.41%-45.76%-53.34% 54Cr
+1.08%+2.47%+53.71%-51.95% 47Cr
-0.81%+1.33%-53.54%-62.03% 37Cr
-0.81%+5.14%-15.69%-32.94% 37Cr
Average +0.42%+2.37%-17.39%-28.44% 244.53Cr
Weighted average by Cap. -0.94%-0.21%+6.00%-30.54%

Financials

2026 *2027 *
Net sales 1.91Cr 20.03L 17.41L 16.2L 14.88L 28.09L 19Cr 28.53L 74.96L 9.52Cr 75.21L 73.56L 32Cr 6.95Cr 72.87L 63.35L 58.96L 54.13L 1.02Cr 70Cr 1.04Cr 2.73Cr 35Cr 2.74Cr 2.68Cr 116.12Cr
Net income -2.89Cr -30.3L -26.34L -24.52L -22.51L -42.51L -29Cr -43.17L -1.13Cr -14Cr -1.14Cr -1.11Cr -48Cr 24L 3L 2L 2L 2L 4L 2.4Cr 4L 9L 1.2Cr 9L 9L 4.01Cr
Net Debt - -
Logo Acarix AB
Acarix AB is a Sweden-based provider of diagnostic solutions for coronary artery disease (CAD). The Company’s primary product CADScor System features phonocardiography technique and algorithms. The CADScor System is fixed with a specific patch to the chest of the patient, with the recording head placed at the forth left intercostal space, and the sensor resting on the sternum. Instructions for the procedure are given on the display for the operator and audio cues guide a patient during the two-minute heart sound recording. After recording, the CAD-score is calculated, and presented on the display of the CADScor Sensor, enabling a physicians, nurses and laboratory technicians to make a rule-out diagnosis.
Employees
-